CVS Health Co. (NYSE:CVS) Shares Bought by Breakwater Capital Group

Breakwater Capital Group raised its holdings in CVS Health Co. (NYSE:CVS) by 7.1% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,401 shares of the pharmacy operator’s stock after acquiring an additional 491 shares during the quarter. Breakwater Capital Group’s holdings in CVS Health were worth $590,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently bought and sold shares of CVS. SOA Wealth Advisors LLC. raised its stake in shares of CVS Health by 4.9% during the 4th quarter. SOA Wealth Advisors LLC. now owns 2,859 shares of the pharmacy operator’s stock worth $226,000 after buying an additional 133 shares during the last quarter. Apella Capital LLC raised its stake in shares of CVS Health by 4.2% during the 4th quarter. Apella Capital LLC now owns 3,378 shares of the pharmacy operator’s stock worth $272,000 after buying an additional 136 shares during the last quarter. Prairie Sky Financial Group LLC raised its stake in shares of CVS Health by 4.1% during the 4th quarter. Prairie Sky Financial Group LLC now owns 3,612 shares of the pharmacy operator’s stock worth $285,000 after buying an additional 141 shares during the last quarter. WealthShield Partners LLC raised its stake in shares of CVS Health by 3.2% during the 4th quarter. WealthShield Partners LLC now owns 4,498 shares of the pharmacy operator’s stock worth $355,000 after buying an additional 141 shares during the last quarter. Finally, Sugarloaf Wealth Management LLC increased its position in CVS Health by 9.5% during the 4th quarter. Sugarloaf Wealth Management LLC now owns 1,639 shares of the pharmacy operator’s stock worth $129,000 after purchasing an additional 142 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Activity at CVS Health

In related news, Director Edward J. Ludwig bought 1,000 shares of the company’s stock in a transaction that occurred on Thursday, May 2nd. The shares were acquired at an average cost of $53.88 per share, for a total transaction of $53,880.00. Following the acquisition, the director now owns 21,630 shares in the company, valued at approximately $1,165,424.40. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.24% of the company’s stock.

CVS Health Stock Performance

Shares of NYSE:CVS opened at $59.06 on Monday. The company has a market cap of $74.14 billion, a P/E ratio of 10.38, a PEG ratio of 0.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.61 and a current ratio of 0.81. CVS Health Co. has a one year low of $52.77 and a one year high of $83.25. The business’s 50-day simple moving average is $59.56 and its 200 day simple moving average is $70.13.

CVS Health (NYSE:CVS) last announced its earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 EPS for the quarter, missing the consensus estimate of $1.69 by ($0.38). The company had revenue of $88.44 billion for the quarter, compared to analysts’ expectations of $89.33 billion. CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The business’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.20 earnings per share. On average, sell-side analysts forecast that CVS Health Co. will post 7.02 earnings per share for the current fiscal year.

Analyst Ratings Changes

CVS has been the subject of a number of recent research reports. The Goldman Sachs Group dropped their price objective on CVS Health from $85.00 to $74.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. UBS Group cut CVS Health from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $85.00 to $60.00 in a research report on Thursday, May 2nd. Argus dropped their price objective on CVS Health from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Bank of America dropped their price objective on CVS Health from $95.00 to $77.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $58.00 price target on shares of CVS Health in a report on Wednesday, June 12th. Eleven research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $75.05.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.